Severe Congenital Neutropenia (SCN) Cell Models for Research

Severe Congenital Neutropenia (SCN) is a rare inherited bone marrow failure syndrome with an estimated incidence of 1–2 per million live births, as reported by the National Institutes of Health (NIH) and the European Bone Marrow Failure Registry. The condition is characterized by persistent absolute neutrophil counts below 0.5 × 10^9/L, leading to recurrent bacterial infections, including pneumonia, sepsis, and skin abscesses. Without treatment, mortality in childhood is high; however, with granulocyte colony-stimulating factor (G-CSF) therapy, survival into adulthood is common, but the risk of progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is approximately 10–20% over 10 years, as noted in the National Cancer Institute (NCI) SEER database and clinical studies. The 5-year survival for SCN patients without hematopoietic stem cell transplantation (HSCT) is estimated at 60–70%, but with HSCT, it exceeds 80%, according to the European Group for Blood and Marrow Transplantation (EBMT). Key risk factors for leukemic transformation include mutations in ELANE, CSF3R, and RUNX1, as well as acquired somatic mutations in the G-CSF receptor (CSF3R).

SCN serves as an ideal model for studying granulopoiesis, innate immunity, and leukemogenesis. The disease is genetically heterogeneous, with at least 20 causative genes identified, including ELANE, HAX1, GFI1, and WAS. Public datasets, such as the NCBI Gene Expression Omnibus (GEO) and the Human Gene Mutation Database (HGMD), provide transcriptomic and mutational data from patient-derived bone marrow samples. Open questions include the molecular mechanisms linking neutropenia to leukemic transformation, the role of endoplasmic reticulum (ER) stress in ELANE-mutant neutrophils, and the development of targeted therapies that reduce the risk of AML. Gene-edited cell models, such as CRISPR knockout or knock-in lines in hematopoietic cell lines like HL-60 or PLB-985, enable functional validation of these genetic variants and facilitate drug screening for compounds that restore neutrophil differentiation.

SCN arises from defects in multiple cellular pathways that impair neutrophil maturation and survival. The major pathways include:

• • Unfolded Protein Response (UPR) and ER Stress: Mutations in ELANE (encoding neutrophil elastase) lead to misfolded protein accumulation in the endoplasmic reticulum, triggering the UPR. This activates PERK, IRE1α, and ATF6, leading to apoptosis of myeloid progenitors.
• • Mitochondrial Apoptosis Pathway: HAX1 mutations disrupt mitochondrial membrane integrity, increasing cytochrome c release and activating caspase-9, leading to premature cell death in the promyelocyte stage.
• • G-CSF Receptor Signaling: Mutations in CSF3R, often acquired, cause truncated receptors that hyperactivate JAK/STAT and MAPK pathways, promoting myeloid proliferation but also increasing leukemia risk.
• • Transcription Factor Dysregulation: Mutations in GFI1 and RUNX1 impair the expression of key granulocytic genes, such as CEBPA and CSF3R, blocking differentiation.

Data from the COSMIC database and ClinVar indicate the following high-frequency genetic alterations in SCN:

These frequencies are based on the NCBI Gene database and the Severe Chronic Neutropenia International Registry (SCNIR).

Deregulated signaling networks in SCN include:

• • JAK/STAT Pathway: Hyperactivation due to CSF3R mutations, leading to increased proliferation and survival of myeloid progenitors.
• • PI3K/AKT/mTOR Pathway: Enhanced signaling promotes cell survival and may contribute to leukemic transformation.
• • MAPK/ERK Pathway: Constitutive activation in CSF3R-mutant cells, driving proliferation.
• • Wnt/β-catenin Pathway: Aberrant activation in some SCN cases, associated with impaired differentiation.
• • Notch Signaling: Reduced Notch activity in HAX1-mutant cells, affecting granulocytic commitment.

Key nodes include STAT3, STAT5, AKT, ERK1/2, and β-catenin, which are potential therapeutic targets.

Common cell lines used in SCN research include:

Organoid models, such as bone marrow organoids derived from induced pluripotent stem cells (iPSCs), are emerging as physiologically relevant systems that recapitulate the bone marrow niche and allow for the study of neutrophil maturation in a 3D environment. These models are particularly useful for testing gene-editing corrections and drug responses.

Animal models for SCN include:

• • Patient-Derived Xenografts (PDX): Immunodeficient mice (e.g., NSG) engrafted with SCN patient bone marrow cells to study leukemic progression and test therapies.
• • Genetically Engineered Mouse Models (GEMM): Mice with Elane knockout or knock-in mutations (e.g., Elane p.Val72Met) that mimic SCN, showing neutropenia and increased apoptosis in myeloid progenitors.
• • Induced Models: Use of CRISPR to introduce HAX1 mutations in mouse hematopoietic stem cells, followed by transplantation into irradiated recipients.
• • Zebrafish Models: Transgenic zebrafish with elane mutations to study granulopoiesis in vivo.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in SCN-associated genes. For example, CRISPR knockout of ELANE in HL-60 cells recapitulates ER stress and apoptosis, while knock-in of CSF3R truncation mutations models G-CSF hypersensitivity. Commercially available, sequence-verified gene-edited cell models (from sources such as those listed in the DepMap portal) accelerate research by providing consistent, validated reagents. These models are essential for studying genotype-phenotype relationships, drug screening, and functional genomics. Isogenic pairs, where the only difference is the target mutation, allow for high-confidence attribution of phenotypic changes to the genetic alteration.

Gene-edited cells are used to validate the functional impact of SCN-associated genetic variants. For example, CRISPR knockout of HAX1 in PLB-985 cells leads to increased apoptosis and reduced neutrophil differentiation, confirming its role in mitochondrial stability. Similarly, knock-in of ELANE mutations in HL-60 cells induces UPR markers (e.g., BiP, CHOP), demonstrating the pathogenic mechanism. These models allow for high-throughput screening of genetic suppressors or enhancers using CRISPR libraries.

Isogenic cell line pairs are ideal for drug screening. For instance, wild-type and CSF3R-mutant HL-60 cells can be used to test compounds that inhibit JAK/STAT signaling, such as ruxolitinib. Resistance mechanisms can be studied by exposing cells to increasing concentrations of a drug and identifying secondary mutations via whole-exome sequencing. Gene-edited models also enable the testing of combination therapies, such as G-CSF plus proteasome inhibitors to reduce ER stress.

CRISPR synthetic lethality screens in SCN gene-edited cells can identify vulnerabilities that are specific to mutant cells. For example, ELANE-mutant cells may be hypersensitive to inhibitors of the unfolded protein response, such as 4μ8C or GSK2606414. These screens can reveal novel biomarkers for patient stratification and therapeutic targets. Additionally, CRISPR activation or interference (CRISPRa/i) screens can identify genes that rescue neutrophil differentiation, providing potential targets for gene therapy.